S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.87 (+0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   908.14 (+0.62%)
NIO   4.63 (-0.86%)
AMD   182.99 (+1.89%)
BABA   72.40 (+1.13%)
T   17.58 (+0.17%)
F   13.19 (+1.00%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   175.56 (-2.53%)
DIS   122.20 (+1.01%)
AMC   3.74 (-13.82%)
PFE   27.86 (+0.29%)
PYPL   66.94 (+0.56%)
XOM   115.40 (+0.37%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.87 (+0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   908.14 (+0.62%)
NIO   4.63 (-0.86%)
AMD   182.99 (+1.89%)
BABA   72.40 (+1.13%)
T   17.58 (+0.17%)
F   13.19 (+1.00%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   175.56 (-2.53%)
DIS   122.20 (+1.01%)
AMC   3.74 (-13.82%)
PFE   27.86 (+0.29%)
PYPL   66.94 (+0.56%)
XOM   115.40 (+0.37%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.87 (+0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   908.14 (+0.62%)
NIO   4.63 (-0.86%)
AMD   182.99 (+1.89%)
BABA   72.40 (+1.13%)
T   17.58 (+0.17%)
F   13.19 (+1.00%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   175.56 (-2.53%)
DIS   122.20 (+1.01%)
AMC   3.74 (-13.82%)
PFE   27.86 (+0.29%)
PYPL   66.94 (+0.56%)
XOM   115.40 (+0.37%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.87 (+0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   908.14 (+0.62%)
NIO   4.63 (-0.86%)
AMD   182.99 (+1.89%)
BABA   72.40 (+1.13%)
T   17.58 (+0.17%)
F   13.19 (+1.00%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   175.56 (-2.53%)
DIS   122.20 (+1.01%)
AMC   3.74 (-13.82%)
PFE   27.86 (+0.29%)
PYPL   66.94 (+0.56%)
XOM   115.40 (+0.37%)

Arcellx (ACLX) Stock Price, News & Analysis

$70.18
-0.27 (-0.38%)
(As of 10:39 AM ET)
Today's Range
$69.54
$70.99
50-Day Range
$53.18
$73.49
52-Week Range
$27.28
$75.10
Volume
18,355 shs
Average Volume
440,882 shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.14

Arcellx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1.9% Downside
$69.14 Price Target
Short Interest
Bearish
9.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.13mentions of Arcellx in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$41.26 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.69) to ($1.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.95 out of 5 stars

Medical Sector

811th out of 939 stocks

Biological Products, Except Diagnostic Industry

139th out of 157 stocks

ACLX stock logo

About Arcellx Stock (NASDAQ:ACLX)

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

ACLX Stock Price History

ACLX Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
ACLX Apr 2024 70.000 call
William Blair Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
See More Headlines
Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ACLX
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$69.14
High Stock Price Target
$87.00
Low Stock Price Target
$39.00
Potential Upside/Downside
-1.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
13 Analysts

Profitability

Net Income
$-70,690,000.00
Pretax Margin
-63.48%

Debt

Sales & Book Value

Annual Sales
$110.32 million
Book Value
$9.97 per share

Miscellaneous

Free Float
49,703,000
Market Cap
$3.71 billion
Optionable
Optionable
Beta
0.02
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives


ACLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings
or view top-rated stocks.

What is Arcellx's stock price target for 2024?

13 brokers have issued 1 year price targets for Arcellx's stock. Their ACLX share price targets range from $39.00 to $87.00. On average, they predict the company's share price to reach $69.14 in the next year. This suggests that the stock has a possible downside of 1.9%.
View analysts price targets for ACLX
or view top-rated stocks among Wall Street analysts.

How have ACLX shares performed in 2024?

Arcellx's stock was trading at $55.50 at the beginning of the year. Since then, ACLX stock has increased by 26.9% and is now trading at $70.45.
View the best growth stocks for 2024 here
.

Are investors shorting Arcellx?

Arcellx saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,610,000 shares, an increase of 5.2% from the February 29th total of 3,430,000 shares. Based on an average daily trading volume, of 458,600 shares, the short-interest ratio is currently 7.9 days. Approximately 9.8% of the shares of the stock are short sold.
View Arcellx's Short Interest
.

When is Arcellx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ACLX earnings forecast
.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) issued its earnings results on Wednesday, February, 28th. The company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.95. The company earned $63.15 million during the quarter, compared to analyst estimates of $20.07 million. Arcellx had a negative net margin of 64.08% and a negative trailing twelve-month return on equity of 20.96%. During the same period in the previous year, the business earned ($0.76) EPS.

What ETF holds Arcellx's stock?

ALPS Medical Breakthroughs ETF holds 36,367 shares of ACLX stock, representing 1.10% of its portfolio.

When did Arcellx IPO?

Arcellx (ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at a price of $15.00-$17.00 per share.

Who are Arcellx's major shareholders?

Arcellx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (9.33%), SR One Capital Management LP (6.46%), Vanguard Group Inc. (4.23%), Vanguard Group Inc. (3.90%), Price T Rowe Associates Inc. MD (2.59%) and Price T Rowe Associates Inc. MD (2.59%). Insiders that own company stock include Christopher Heery, Enterprise Associates 15 New, Jill Carroll, Michelle Gilson, Olivia C Ware, Rami Elghandour, Scott D Sandell and Sr One Capital Management, Llc.
View institutional ownership trends
.

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACLX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners